comprehensive -WSS

comprehensive

author：focus 2025-08-12 09:11:40 - browse：2865

A doctor climbs up a red ladder to a vine shaped like a DNA — biotech coverage from STAT — Adobe

Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the hall, and helps her 8-year-old daughter Addi slide into a set of contraptions that squeeze and suck out the thick mucus constantly threatening to choke her airways closed. She feeds Addi breakfast through a stomach tube and makes sure she has the right mix of the 28 different medications required to keep her free of pain, infections, and seizures. At some point, Rasberry’s five other children will wake up and start to get ready for school, including her youngest, Oliver. At 3-and-a-half years old, he’s a typical toddler — always running and giggling and getting into things. You would never know that he and Addi were born with the same mutation lurking in their DNA, a genetic glitch that causes a fatal neurodegenerative disease called metachromatic leukodystrophy, or MLD.

“When Addi was this age she had lost the ability to speak and was already using a ventilator to sleep at night,” Rasberry said. “It’s amazing to see how well Ollie is doing in comparison. And it’s all because of the gene therapy.”

Three years ago, when Ollie was just 6 months old, he and Victoria traveled from their home in Texas to Milan, to receive a gene therapy treatment that adds a healthy version of the defective gene into patients’ own stem cells. At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., too.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

focus

WSS

Anxious about a speech? A startup wants you to pop a minty cardiac drug

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

Stanford updates investigation of president’s past research

Readers respond to H5N1 and livestock movements, and more

Big Tobacco's 'harm reduction': Is it for real, or a sham?

It's time to retire 'poor historian' from clinicians' vocabularies

Wikipedia

comprehensive

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Cytokinetics CEO stresses company can launch heart drug on its own

State Dept. review finds Biden bears some blame for Afghanistan failures

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Medical leaders decry Supreme Court decision on affirmative action

Addiction experts warn against a second 'war on drugs'

Moonlake's readout produced a cash windfall. Risks remain

With measles on the rise, a personal story of a devastating disease

In age of alternative facts, a scholarly course on calling out crap

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

entertainment

Cytokinetics CEO stresses company can launch heart drug on its own

Celebrate National Dole Whip Day for 3 days this week at Disney

Big Tobacco's 'harm reduction': Is it for real, or a sham?

HIV vaccine remains elusive. Immunologists keep trying new ideas

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

focus

hotspot

hotspot

hotspot